Disclosure under Regulation 30 of SEBI Listing Regulations.
HIKAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hikal Limited has received the Good Manufacturing Practices (GMP) certificate from ANVISA, Brazil's health regulatory agency, for its Jigani manufacturing unit in Bengaluru. The ANVISA audit was conducted from April 14 to April 18, 2025, and covered multiple Active Pharmaceutical Ingredients (APIs). This certification enables the company to manufacture and supply pharmaceutical inputs for the Brazilian market. The Jigani unit is a key pharmaceutical manufacturing facility for Hikal.
This is a positive development for Hikal as the ANVISA GMP certification opens up the Brazilian pharmaceutical market for the company's API products, potentially adding a new revenue stream. Brazil is one of the largest pharmaceutical markets in Latin America, and this approval strengthens Hikal's global regulatory footprint.